- Home
- FLC vs INBX Comparison
FLC vs INBX Comparison
Compare FLC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | INBX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.4M | 1.5B |
| IPO Year | 2003 | 2024 |
Fundamental Metrics
Financial Performance| Metric | FLC | INBX |
|---|---|---|
| Price | $16.24 | $109.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 18.6K | ★ 317.9K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $15.89 | $26.19 |
| 52 Week High | $18.09 | $155.29 |
Technical Indicators
Market Signals| Indicator | FLC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 25.15 | 51.54 |
| Support Level | $15.89 | $70.23 |
| Resistance Level | $17.00 | $131.01 |
| Average True Range (ATR) | 0.10 | 10.16 |
| MACD | -0.03 | -1.30 |
| Stochastic Oscillator | 0.00 | 43.91 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.